top of page
Axol Bioscience raises $2.8M to expand its human-based in vitro disease models
13 January 2026 Edinburgh-based CRO Axol Bioscience announces it has raised $2.8M in funding led by US life sciences specialist BroadOak Capital Partners. This investment will build upon Axol's double-digit revenue growth in 2025 to further support the development of its human-based in vitro disease models and its expansion to the US market. "We’re proud to partner with BroadOak, a global leader in life sciences investing. Their expertise and support, alongside our long-t
Muotri Lab's Pitt Hopkins syndrome patient-derived brain organoids lay the foundation for gene therapy trial
31 January 2026 Mahzi Therapeutics-sponsored Phase 1/2 study to assess safety and efficacy of MZ-1866 gene therapy for children and adults with Pitt Hopkins syndrome is about to start. The trial was announced by Mahzi in 2025, highlighting the sponsor's collaboration with the Pitt Hopkins Research Foundation and the Muotri Lab at UC San Diego in developing this long awaited treatment. Pitt-Hopkins syndrome is a rare genetic disorder caused by mutations in the transcriptio
bottom of page